Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Approvals Action
Lilly adds alternative Alimta brands
As genericisation looms for its $36 million lung cancer treatment Alimta, Eli Lilly has registered new brand names for the product.
Quarterly Industry Review
Q3 2015: Lots of suggestions but no action
Aussie pharma has had a challenging third quarter of 2015 in the aftermath of strategic negotiations with government falling over. Suggestions for improvement abound but little or nothing is being done.
Open Forum
What a Kardashian taught pharma
What can Kim Kardashian teach Australian pharma about social media? Amanda Turnill and David Bruce-Smith from Baker & McKenzie explain.
Pipeline Monitor
Novartis files biosim for Enbrel
Novartis' generic arm, Sandoz has had its filing for US approval of a biosimilar version of Pfizer's Enbrel accepted by the FDA.